BPO 0.00% 0.3¢ bioprospect limited

bpo still on track....holding up well, page-7

  1. 6,187 Posts.
    lightbulb Created with Sketch. 497
    Sooner the better for all concerned L. Both companies have great potential and should be working to their strengths.

    As for Bioeffectives in husbandry fields, the most likely matter at the root of this dispute as SLA are not saying exactly what is at dispute. It must be realised that the direction and pursuit of companion pet and equine commercial ready products is the fastest and easiest path. While a surface look would suggest that feedlot additives could be lucrative, unfortunately residuals in table products is a very tricky thing to control. It is in fact so complex it should not be the first path to go down. I'm aware that R&D in Bio-A feedlot products in some Asian countries could be far easier and quicker to get done, but to what end given the potential roadblocks and litigation that could pop up with a political wind of change. Some things have to be done "right", and global product acceptance dictates it is the "western" way at present, its slow, its tedious but accepted.

    I understand that all potential BPO product R&D has been farmed out which substantially reduces costs - except Bioeffectives - that in itself says something as to its commitment.
 
watchlist Created with Sketch. Add BPO (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.